Intriguingly, despite studies by Kim et al. [9] and Kamiya et al. [10] indicating that the positive anti-SSA and anti-SSB antibodies does not reduce the mortality risk in patients with pSS-ILD, a pooled analysis reveals a significant association between antibody positivity and a decreased mortality risk in pSS-ILD (Fig. 3b and c). Here, SSB is linked to interstitial lung disease.